Hydroxycarboxylic Acid Receptor 2 (HCAR2) Antibody
260€ (50 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Hydroxycarboxylic Acid Receptor 2 (HCAR2) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx214867
tested applications
ELISA, IHC
Description
HCAR2 Antibody is a Rabbit Polyclonal against HCAR2.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Hydroxycarboxylic Acid Receptor 2 (HCAR2) |
| Host | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Recommended Dilution | ELISA: 1/2000 - 1/10000, IHC: 1/100 - 1/300. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Purification | Antigen Affinity Chromatography. |
| Size 1 | 50 µl |
| Size 2 | 100 µl |
| Form | Liquid |
| Tested Applications | ELISA, IHC |
| Buffer | PBS, pH 7.4, containing 0.05% NaN3 and 40% Glycerol. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q8TDS4 |
| Gene ID | 338442 |
| OMIM | 609163 |
| Alias | HCAR2,PUMAG,G-protein coupled receptor HM74A,Nicotinic acid receptor,Nic1,G protein-coupled receptor 109A,Niacr1,niacin receptor 1,HCA2,HM74a,HM74b,NIACR1,Puma-g,GPR109A |
| Background | Antibody anti-HCAR2 |
| Status | RUO |
Descripción
HCAR2, also known as GPR109A, is a G protein-coupled receptor activated by nicotinic acid (niacin) and endogenous metabolites such as β-hydroxybutyrate (BHB). It is highly expressed in adipose tissue, immune cells, and the gut, where it plays a pivotal role in lipid metabolism, inflammation, and energy homeostasis. In adipocytes, HCAR2 activation inhibits cAMP production via Gi/o proteins, leading to the suppression of lipolysis and reduced free fatty acid release, which lowers circulating triglyceride levels. HCAR2 also mediates anti-inflammatory effects in immune cells, particularly in macrophages, by inhibiting pro-inflammatory cytokine production and promoting anti-inflammatory pathways, making it a key target in atherosclerosis and inflammatory diseases. HCAR2 is activated during fasting or ketogenic states through β-hydroxybutyrate, linking it to metabolic adaptations and energy conservation. Dysregulation of HCAR2 is implicated in metabolic disorders, cardiovascular disease, and neuroinflammation. Niacin-based therapies targeting HCAR2 are used to improve lipid profiles and manage dyslipidemia, highlighting its clinical relevance.
Related Products
Hydroxycarboxylic Acid Receptor 2 (HCAR2) Antibody
HCAR2 Antibody is a Rabbit Polyclonal against HCAR2.
Ver ProductoHydroxycarboxylic Acid Receptor 2 (HCAR2) Antibody
HCAR2 Antibody is a Rabbit Polyclonal against HCAR2.
Ver ProductoHydroxycarboxylic Acid Receptor 2 (HCAR2) Antibody
Hydroxycarboxylic Acid Receptor 2 (HCAR2) Antibody is a Rabbit Polyclonal antibody against Hydroxycarboxylic Acid Receptor 2 (HCAR2).
Ver Producto